Table 2.
Awareness and interest in genomic SNP testing for prostate cancer risk
| Item | PRAP group | Urology group | p |
|---|---|---|---|
| N (%) | N (%) | ||
| Awareness | |||
| Awareness of genomic SNP testing for PC risk | 0.38 | ||
| Not aware | 28 (70.0) | 34 (85.0) | |
| A little | 4 (10.0) | 1 (2.5) | |
| Somewhat | 4 (10.0) | 3 (7.5) | |
| Quite | 2 (5.0) | 2 (5.0) | |
| Very aware | 2 (5.0) | 0 (0.0) | |
| Awareness of genomic SNP tests on the Internet | |||
| Not aware | 40 (100.0) | 38 (95.0) | 0.49 |
| Missing | 0 (0.0) | 2 (5.0) | |
| Interest | |||
| Interest in genomic SNP testing if standard-of-care | <0.001 | ||
| Strongly disagree | 0 (0.0) | 6 (15.0) | |
| Sort of disagree | 0 (0.0) | 6 (15.0) | |
| Neither agree nor disagree | 0 (0.0) | 4 (10.0) | |
| Sort of agree | 10 (25.0) | 10 (25.0) | |
| Strongly agree | 30 (75.0) | 14 (35.0) | |
| Interest change if ancestry markers revealed | 0.58 | ||
| No change | 20 (50.0) | 17 (42.5) | |
| Maybe more interest | 12 (30.0) | 17 (42.5) | |
| Definitely more interest | 8 (20.0) | 6 (15.0) |
Bold: Results significant (p < 0.05).